NOVEL NPR-B AGONISTS

摘要

Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D- amino acid residues connected to one another via peptide bonds. Also disclosed are methods of treating C-type natriuretic peptide (CNP)-mediated disorders, including glaucoma and/or elevated intraocular pressure, in a subject using pharmaceutical compositions that include a novel NPR-B agonist as described herein.